Article Text

Download PDFPDF

P1.041 HIV Drug-Resistance Mutations Within HIV Reverse-Transcriptase Among Patients Receiving HAART in Kazakhstan
  1. A Utegenova,
  2. N Dzissyuk
  1. Republican centre for prevention and control of AIDS, Almaty, Kazakhstan


Introduction Drug resistance is very serious clinical problem, it is often cause of treatment failure among HIV-positive patients on HAART. Antiretroviral therapy (ART) was started in 2005. The aim of this study is to analyse of the prevalence of drug-resistance mutations (DRMs) within reverse-transcriptase (RT) among HIV-positive on first-line ART.

Methods 205 HIV-positive patients on (AZT/3TC + NVP or EFV) with viral load more than 1500c/ml, and 37 ART-naïve were examined. HIV RNA extraction, RT-PCR and sequencing pol gene were assayed with the kits “ViroSeq HIV-1 genotyping systems” (USA) or “AmpliSens-HIV-genotype” (Russia). Sequencing was performed on ABI3130. To interpret results the programme of the Stanford University ( was used. HIV subtyping was performed using “REGA HIV-1/2” (, “Comet HIV 1/2” (

Results Among the received RT sequences HIV-1 subtypes A(A1) (71.1%), CRF02_AG (25.0%), B (2.9%), CRF03_AB (0.5%), cpx06 (0.5%) were identified. Overall, 34.6% (71/205) patients’ treatment failure due to drug-resistance virus. In 22.5% cases were detected drug-resistance mutations (DRMs) to both NRTI and NNRTI. There was no correlation between the formation of drug resistance and the HIV-1 subtype A, B and A/G (35.9%, 33.3% and 37.3%, respectively).

In the NRTI group were identified M184V, T215F, and K219Q mutations. Among DRMs to NNRTI G190A/S, K103N, K101E/H and Y181C/V mutations were registered. Among ART-naïve patients DRMs was not detected.

Conclusion In Kazakhstan the HIV resistance was determined in 3.9% among HAART treated patients and mostly to 3TC, NVP and EFV. It’s necessary to increase the variety of antiretroviral drugs used in the country.

  • HIV
  • Mutations
  • Resistance

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.